Document is current
Any future updates will be listed below
-
Authors
Pacyna, Clarissa N. http://orcid.org/0000-0002-4404-8183
Anandapadamanaban, Madhanagopal
Loudon, Kevin W.
Hay, Iain M.
Perisic, Olga
Li, Ruoyan http://orcid.org/0000-0001-5337-9729
Byrne, Matthew
Allen, Laura
Roberts, Kirsty
Hooks, Yvette
Warren, Anne Y. http://orcid.org/0000-0002-1170-7867
Stewart, Grant D. http://orcid.org/0000-0003-3188-9140
Clatworthy, Menna R.
Teichmann, Sarah A.
Behjati, Sam http://orcid.org/0000-0002-6600-7665
Campbell, Peter J. http://orcid.org/0000-0002-3921-0510
Williams, Roger L. http://orcid.org/0000-0001-7754-4207
Mitchell, Thomas J. http://orcid.org/0000-0003-0761-9503
- License Information
-
More Information
Article History
Received: 21 March 2024
Revised: 5 July 2024
Accepted: 14 August 2024
First Online: 13 September 2024
Competing interests
: S.A.T. is a scientific advisory board member of ForeSite Labs, Qiagen and Element Biosciences, and a co-founder and equity holder of TransitionBio and EnsoCell Therapeutics, and a part-time employee of GlaxoSmithKline. P.J.C. is an academic co-founder for Quotient Therapeutics.
: All research in this study involving human subjects, human material, or human data is in accordance with the Declaration of Helsinki. Human material was obtained from patients enroled in an UK NHS REC approved study (reference 16/EE/0394). In accordance with the REC requirements, consent was obtained from all subjects. As no patient photographs were used, consent to publish images was not applicable.
